ilmofosine

used in treatment of colonic adenocarcinoma in rats; structure given in first source; RN given refers to hydroxide inner salt

Also Known As:

1-hexadecylmercapto-2-methoxymethyl-3-propylphosphoric acid monocholine ester; 1-mercaptohexadecyl-2-methoxymethyl-syn-glycero-3-phosphocholine; BM 41.440; BM-41440; HMMPAM; SH-MM-lysolecithin; ilmofosine, hydroxide inner salt, (+-)-isomer; 3,5-Dioxa-9-thia-4-phosphapentacosan-1-aminium, 4-hydroxy-7-(methoxymethyl)-N,N,N-trimethyl-, (2S-(1(R*(R*)),2alpha,3abeta,7abeta))-

Networked: 24 relevant articles (0 outcomes, 8 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Barrias, Emile: 1 article (11/2019)
2.	Calogeropoulou, Theodora: 1 article (11/2019)
3.	Reignault, Lissa Catherine: 1 article (11/2019)
4.	de Souza, Wanderley: 1 article (11/2019)
5.	Blitterswijk, Wim J van: 1 article (05/2014)
6.	Moolenaar, Wouter H: 1 article (05/2014)
7.	Verheij, Marcel: 1 article (05/2014)
8.	Derry, Christine: 1 article (02/2004)
9.	Giantonio, Bruce J: 1 article (02/2004)
10.	McAleer, Cecilia: 1 article (02/2004)

Related Diseases

1.	Neoplasms (Cancer) 02/01/1992 - "Clinical phase II trials with ilmofosine including the tumor types with in vitro sensitivity are warranted if adequate plasma concentrations of this agent can be reached in patients." 11/01/1987 - "BM 41.440 was evaluated in a multicenter phase I study in patients (pts) with refractory cancers. " 01/01/1996 - "We conclude that ilmofosine is inactive in this tumor at this dose and schedule." 02/01/1992 - "We conclude that ilmofosine is active against a variety of tumors in vitro. " 02/01/1992 - "Preclinical activity of ilmofosine against human tumor colony forming units in vitro."
2.	Lethargy 01/01/1995 - "In a Phase I trial of a weekly 2 hour infusion schedule of ilmofosine, a syndrome of lethargy, diminished performance status, and mild hepatotoxicity was dose-limiting at 550 mg/m2. "
3.	Bronchogenic Carcinoma 01/01/1996 - "A phase II trial of ilmofosine in non-small cell bronchogenic carcinoma." 01/01/1996 - "We have conducted a study of ilmofosine (1-hexadecylthio; 2-methoxyethyl-rac-glycero-3-phosphocholine) in non-small cell bronchogenic carcinoma, using a schedule of continuous infusion for 5 days and a dose of 300 mg/m2/day. "
4.	Leukemia 12/01/1988 - "Effects of thioether phospholipid BM 41.440 on protein kinase C and phorbol ester-induced differentiation of human leukemia HL60 and KG-1 cells." 11/01/1987 - "Screening for cytotoxicity in the clonogenic assay in human tumor xenografts and L1210 mouse leukemia revealed comparable dose-dependent effects of the alkyl lysophospholipid ET-18-OCH3 and the thioether lipid BM 41.440. " 11/01/1987 - "The effects of 2-lysophosphatidylcholine (2-LPC), the alkyl lysophospholipid derivatives (ALP) 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine (ET-18-OCH3) and 1-O-hexadecyl-sn-glycero-3-phospho-trimethyl-ammonio-hexanol, the 2-acetamide analog of platelet-activating factor (PAF) 1-O-octadecyl-2-acetamide-sn-glycero-3-phosphocholine, the thioether lysophospholipid derivative (TLP) BM 41.440 and the ether-linked lipoidal amine CP-46,665 on tritiated thymidine uptake and trypan blue dye exclusion were tested in vitro in various freshly explanted cell samples from human nonneoplastic bone marrow and human leukemias. "
5.	Neoplasm Metastasis (Metastasis) 01/01/1992 - "We thus conclude that treatment with oral ilmofosine is not effective in patients with liver metastases due to various malignancies." 12/01/1991 - "Ilmofosine caused a significant dose-related response on tumor growth and metastases, expressed in terms of tumor diameter, tumor weight, survival time and number of metastases-free animals as compared to sham-treated and positive (cyclophosphamide) controls. "

Related Drugs and Biologics

1.	Sulfides (Thioethers)
2.	Phospholipids (Phosphatides)
3.	Lysophospholipids
4.	Ether (Diethyl Ether)
5.	Lipids
6.	Phosphorylcholine (Phosphocholine)
7.	ilmofosine
8.	edelfosine
9.	Cytostatic Agents
10.	Methylcellulose (BFL)

Related Therapies and Procedures

1.	Therapeutics